Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report)’s stock price gapped up prior to trading on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $16.56, but opened at $18.00. Daiichi Sankyo shares last traded at $18.17, with a volume of 182,633 shares traded.
The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.08. Daiichi Sankyo had a return on equity of 16.31% and a net margin of 12.13%. The firm had revenue of $3.77 billion during the quarter, compared to analyst estimates of $3.58 billion.
Analyst Ratings Changes
A number of equities research analysts have weighed in on DSNKY shares. Jefferies Financial Group lowered Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Zacks Research downgraded Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Daiichi Sankyo presently has a consensus rating of “Reduce”.
View Our Latest Analysis on DSNKY
Daiichi Sankyo Trading Up 10.3%
The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The stock’s 50 day moving average price is $17.77 and its 200-day moving average price is $17.66. The stock has a market capitalization of $34.02 billion, a P/E ratio of 18.63, a P/E/G ratio of 1.99 and a beta of -0.11.
About Daiichi Sankyo
Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.
Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.
Featured Articles
- Five stocks we like better than Daiichi Sankyo
- 3 Tech Stocks Boosting Buyback Capacity in the Face of the Sector’s Recent Tumble
- Strategy Pauses Bitcoin Buys to Focus on Preferred Stock Buybacks
- Uranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?
- Royal Caribbean Buys the Beach as Norwegian Fixes the Ship
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
